Immuneering Corp Cl A (IMRX)

$6.81 +0.42 (6.57%)
Market Cap 412.60M
Revenue (ttm) 0.00
Net Income (ttm) -61.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,464,800
Avg Vol 1,228,152
Day's Range N/A - N/A
Shares Out 64.57M
Stochastic %K 89%
Beta 0.46
Analysts Strong Sell
Price Target $16.83

Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Cor...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 500 8080
Address:
245 Main Street, Second Floor, Cambridge, United States
ibaian
ibaian Dec. 25 at 5:52 AM
$IMRX $ 10 before 7th Jan
0 · Reply
theory2
theory2 Dec. 25 at 2:16 AM
$IMRX not big vol but some sweeps yesterday and today in 10s and 7s!
0 · Reply
LolloTek
LolloTek Dec. 24 at 3:53 PM
$IMRX get ready for the next year IMRX fellas 🎉
0 · Reply
Mwd04
Mwd04 Dec. 24 at 3:51 PM
$IMRX loading up under $7. This will be free money to hop in before January 7
0 · Reply
YouVSYou
YouVSYou Dec. 24 at 3:44 PM
$IMRX here we go
0 · Reply
kubota2323
kubota2323 Dec. 24 at 3:36 PM
$IMRX $ALMS $PEPG Giddy up.
0 · Reply
OptimistJP
OptimistJP Dec. 24 at 12:59 PM
$IMRX That pesky number 666. Extended hours $6.66+0.27 (+4.23%) Bid x Size $6.55 x 200 Ask x Size $6.69 x 1,000
0 · Reply
OptimistJP
OptimistJP Dec. 24 at 12:39 PM
$IMRX A run over $7 today would be a very nice way to say, "Merry Christmas to all my friends on Stocktwits!" Opti
0 · Reply
ibaian
ibaian Dec. 24 at 4:40 AM
$IMRX $10 before 6th January 2026
0 · Reply
kcarroll92
kcarroll92 Dec. 24 at 3:55 AM
$IMRX great day here
0 · Reply
Latest News on IMRX
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026

Dec 23, 2025, 8:00 AM EST - 1 day ago

Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026

Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA

Dec 17, 2025, 4:05 PM EST - 7 days ago

Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA

Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)

Dec 16, 2025, 8:00 AM EST - 8 days ago

Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)

Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 8:00 AM EST - 4 weeks ago

Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference

Immuneering Corporation (IMRX) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 9:11 PM EST - 6 weeks ago

Immuneering Corporation (IMRX) Q3 2025 Earnings Call Transcript

Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates

Nov 12, 2025, 4:05 PM EST - 6 weeks ago

Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates

Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025

Nov 4, 2025, 4:05 PM EST - 7 weeks ago

Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025

Immuneering Corporation - Special Call

Sep 29, 2025, 4:37 PM EDT - 3 months ago

Immuneering Corporation - Special Call

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

Sep 26, 2025, 4:01 PM EDT - 3 months ago

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst

Sep 25, 2025, 2:19 PM EDT - 3 months ago

Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

Sep 25, 2025, 12:08 AM EDT - 3 months ago

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi

Sep 24, 2025, 4:05 PM EDT - 3 months ago

Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi

Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Sep 24, 2025, 4:01 PM EDT - 3 months ago

Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

Sep 16, 2025, 7:00 AM EDT - 3 months ago

Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

Sep 10, 2025, 7:00 AM EDT - 3 months ago

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

Immuneering Announces Closing of $25 Million Private Placement

Aug 26, 2025, 4:05 PM EDT - 4 months ago

Immuneering Announces Closing of $25 Million Private Placement

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib

Aug 25, 2025, 8:00 AM EDT - 4 months ago

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib

LLY

Immuneering Announces $25 Million Private Placement

Aug 21, 2025, 8:00 AM EDT - 4 months ago

Immuneering Announces $25 Million Private Placement

Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 13, 2025, 4:05 PM EDT - 4 months ago

Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates

Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib

Jul 9, 2025, 8:00 AM EDT - 6 months ago

Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

Jun 17, 2025, 6:00 AM EDT - 6 months ago

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

Jun 16, 2025, 8:00 AM EDT - 6 months ago

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

Immuneering to Present at the Jefferies Global Healthcare Conference

May 29, 2025, 8:00 AM EDT - 7 months ago

Immuneering to Present at the Jefferies Global Healthcare Conference

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

May 5, 2025, 4:05 PM EDT - 8 months ago

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 8:00 AM EDT - 9 months ago

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Immuneering Corporation Announces Grant of Inducement Award

Mar 21, 2025, 4:30 PM EDT - 9 months ago

Immuneering Corporation Announces Grant of Inducement Award

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 20, 2025, 4:05 PM EDT - 9 months ago

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Mar 20, 2025, 7:00 AM EDT - 9 months ago

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 3, 2025, 4:05 PM EST - 11 months ago

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Why Is Immuneering Stock Trading Higher On Tuesday?

Jan 7, 2025, 9:28 AM EST - 1 year ago

Why Is Immuneering Stock Trading Higher On Tuesday?

Immuneering Launches Pancreatic Cancer Advisory Board

Dec 19, 2024, 8:00 AM EST - 1 year ago

Immuneering Launches Pancreatic Cancer Advisory Board

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Dec 13, 2024, 2:10 PM EST - 1 year ago

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

FOLD

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Dec 12, 2024, 8:00 AM EST - 1 year ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Nov 27, 2024, 8:00 AM EST - 1 year ago

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 13, 2024, 4:05 PM EST - 1 year ago

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Sep 12, 2024, 4:05 PM EDT - 1 year ago

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

May 7, 2024, 4:05 PM EDT - 1 year ago

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

Immuneering Recognizes Melanoma Awareness Month

May 6, 2024, 4:30 PM EDT - 1 year ago

Immuneering Recognizes Melanoma Awareness Month

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

Apr 9, 2024, 12:00 PM EDT - 1 year ago

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Apr 3, 2024, 4:05 PM EDT - 1 year ago

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Mar 27, 2024, 8:00 AM EDT - 1 year ago

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone

Mar 19, 2024, 2:19 AM EDT - 1 year ago

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

Mar 14, 2024, 7:00 AM EDT - 1 year ago

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

Immuneering Appoints Thomas J. Schall, Ph.D.

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Immuneering Appoints Thomas J. Schall, Ph.D.

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors

Mar 11, 2024, 8:00 AM EDT - 1 year ago

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

Mar 6, 2024, 8:00 AM EST - 1 year ago

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

BLRX CADL ONCY

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

Mar 5, 2024, 5:00 PM EST - 1 year ago

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

Immuneering to Participate in the Cowen 44th Annual Health Care Conference

Mar 4, 2024, 8:00 AM EST - 1 year ago

Immuneering to Participate in the Cowen 44th Annual Health Care Conference

ibaian
ibaian Dec. 25 at 5:52 AM
$IMRX $ 10 before 7th Jan
0 · Reply
theory2
theory2 Dec. 25 at 2:16 AM
$IMRX not big vol but some sweeps yesterday and today in 10s and 7s!
0 · Reply
LolloTek
LolloTek Dec. 24 at 3:53 PM
$IMRX get ready for the next year IMRX fellas 🎉
0 · Reply
Mwd04
Mwd04 Dec. 24 at 3:51 PM
$IMRX loading up under $7. This will be free money to hop in before January 7
0 · Reply
YouVSYou
YouVSYou Dec. 24 at 3:44 PM
$IMRX here we go
0 · Reply
kubota2323
kubota2323 Dec. 24 at 3:36 PM
$IMRX $ALMS $PEPG Giddy up.
0 · Reply
OptimistJP
OptimistJP Dec. 24 at 12:59 PM
$IMRX That pesky number 666. Extended hours $6.66+0.27 (+4.23%) Bid x Size $6.55 x 200 Ask x Size $6.69 x 1,000
0 · Reply
OptimistJP
OptimistJP Dec. 24 at 12:39 PM
$IMRX A run over $7 today would be a very nice way to say, "Merry Christmas to all my friends on Stocktwits!" Opti
0 · Reply
ibaian
ibaian Dec. 24 at 4:40 AM
$IMRX $10 before 6th January 2026
0 · Reply
kcarroll92
kcarroll92 Dec. 24 at 3:55 AM
$IMRX great day here
0 · Reply
BearTamerTrading
BearTamerTrading Dec. 24 at 2:33 AM
Market Alerts — Bear Tamer Trading Top Plays Recap | Part 3 of 3 🔥 $METC — Continued strength after-hours, holding trend cleanly. 🔥 $YCBD — Late push with buyers stepping in near highs. 🔥 $ASPC — Early spike faded post-close, solid example of why trims matter. 🔥 $SUUN — Stayed active across sessions with sustained momentum. 🔥 $IMRX — Remains on watch with continued interest after-hours. 👉 Watch the replay here: https://youtube.com/@beartamertrading?si=BlnEs_e88aSX3bvD Congrats to everyone who caught these live on Market Alerts today 💰👏
2 · Reply
BearTamerTrading
BearTamerTrading Dec. 24 at 2:17 AM
Market Alerts — Bear Tamer Trading Top Plays Recap | Part 1 of 3 🔥 $IMRX — Held strength into after-hours with steady continuation and controlled price action. 🔥 $HIHO — After-hours momentum push after buyers reclaimed key levels. 🔥 $TRIB — Biotech name seeing renewed interest following intraday consolidation. 🔥 $TIVC — Low-float mover holding a tight range post-close. 🔥 $OPTX — Volatile downside flush after-hours creating bounce/scalp opportunities. 👉 Watch the replay here: https://youtube.com/@beartamertrading?si=BlnEs_e88aSX3bvD Congrats to everyone who caught these live on Market Alerts today 💰👏
2 · Reply
BinaryLogic
BinaryLogic Dec. 24 at 1:36 AM
$IMRX Here is what happened from the IMM-1-104 Phs-2 readout in May-2025. As I mentioned yesterday (12/22), the Company is scheduled to be added to the NBI and Phs-2/3 transition upcoming on pancreatic cancer candidate. https://www.stocktitan.net/news/IMRX/immuneering-to-announce-12-month-overall-survival-data-from-phase-2a-5iato84ed1h6.html
0 · Reply
QuantitativeTrading_
QuantitativeTrading_ Dec. 23 at 8:45 PM
Phase 2a OS update — $IMRX +8.14% intraday 🚀 ➤ RVOL 1.10 vs AVol 1.98M — above‑normal turnover confirms buy‑side ➤ Short Float 14.93%; Short Ratio 3.68 — elevated short interest on the tape ➤ 40 funds with +48.1% increase; ATR 0.47 (~7% of $6.45) = concentrated, rising institutional interest biotech
0 · Reply
topstockalerts
topstockalerts Dec. 23 at 7:43 PM
$IMRX Is it going higher?
2 · Reply
RealMcCoy
RealMcCoy Dec. 23 at 7:14 PM
$IMRX IMRX does not need to beat RVMD on ORR. It needs to extend the OS tail — which is exactly what Deep Cyclic Inhibition is designed to do. If Jan 7 shows late curve separation, the biology thesis is validated.
0 · Reply
RealMcCoy
RealMcCoy Dec. 23 at 7:09 PM
$IMRX If atebimetinib shows: Durable OS without toxicity blow-ups No rapid late deaths (tail preservation) → IMRX does not need to “beat” RVMD, just coexist as: A chemo-backbone enhancer Or future combo partner That alone supports multi-billion peak sales logic.
0 · Reply
Mwd04
Mwd04 Dec. 23 at 6:30 PM
$IMRX loaded up big the last few weeks
0 · Reply
YouVSYou
YouVSYou Dec. 23 at 5:20 PM
Eyeing $IMRX 6.08 for a bounce
0 · Reply
Uatu616
Uatu616 Dec. 23 at 5:02 PM
$IMRX looks like the circus is back in town
0 · Reply
SocioCobb
SocioCobb Dec. 23 at 4:33 PM
$IMRX Form 4, October 4th
0 · Reply
JohnTrack
JohnTrack Dec. 23 at 4:17 PM
$IMRX watching for continuation!
0 · Reply